Minims (Pilocarpine Nitrate)

Pilocarpine nitrate is a direct muscarinic (M3) receptor agonist. Activation of these receptors contracts the iris sphincter muscle, producing miosis, and stimulates the trabecular meshwork to increase aqueous humor drainage, thereby reducing intra‑ocular pressure.

The dosing regimen for Minims is determined by the prescribing clinician based on the patient’s condition, response, and tolerance. The prescriber will specify the number of drops, frequency, and duration appropriate for each individual case.

Safety of pilocarpine nitrate in pregnancy and lactation has not been established. Healthcare providers should evaluate the potential benefits against possible risks before prescribing Minims to pregnant or nursing women.

To request Minims, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative class for lowering intra‑ocular pressure includes prostaglandin analogues such as latanoprost, which increase uveoscleral outflow. Pilocarpine nitrate, a miotic, works by enhancing trabecular outflow and inducing miosis. Choice depends on patient tolerance, target IOP reduction, and clinician preference.

Store Minims at room temperature, preferably below 25 °C, in the original container. Protect the product from direct light and moisture. Do not freeze. Keep the vial tightly closed when not in use.

Minims is applied as an ocular drop. The patient should wash hands, tilt the head back, pull down the lower eyelid, and place the prescribed number of drops into the conjunctival sac. Close the eye gently and avoid blinking excessively for a few seconds.

Serious risks include acute angle‑closure glaucoma triggered by excessive miosis, severe allergic reactions such as angioedema, and systemic cholinergic toxicity manifesting as bradycardia or hypotension. Patients should seek immediate medical attention if they experience sudden eye pain, vision loss, or systemic symptoms.

Minims should be avoided in individuals with known hypersensitivity to pilocarpine or other cholinergic agents, in patients with narrow anterior chamber angles at risk for angle‑closure glaucoma, and in those with uncontrolled asthma or severe COPD where cholinergic stimulation could worsen bronchospasm.